Safety specification

This part of an RMP provides a synopsis of a medicinal product’s safety. It should be a summary of:
• The important identified risks
• Important potential risks
• Missing information
It should also address:
• Populations potentially at risk (where the product is likely to be used in labelled and off-labelled use)
• Safety questions which warrant further investigation during the post-authorization period